Good day and thank you for standing by. Welcome to Idorsia's TRYVIO Investor Q&A Webcast and Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I ...
Ad hoc announcement pursuant to Art. 53 LR Idorsia delivers on its upgraded 2025 guidance, with strong QUVIVIQ sales growth, disciplined investment, and a significantly improved bottom line.Focused ...
Idorsia announced a cost reduction target to reduce operating expenses by approximately 50%. Idorsia also sold its APAC (ex-China) license for CHF 400 million to extend its cash burn until 2024. We ...
Idorsia secures $350 million in funding through a collaboration agreement with Viatris, solving immediate liquidity concerns. FDA approves Idorsia's Aprocitentan drug. There is a potential peak sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results